The Eligible Patient Who Does Not Want the Randomization
A 71-year-old woman with treatment-resistant depression is referred to a randomized, double-blind trial comparing an investigational augmentation agent to placebo, added to her existing antidepressant. She meets all eligibility criteria. During consent, she says: 'I'll do it, but only if I'm guaranteed the real drug - I've already wasted two years on things that didn't work.' The investigator explains randomization and the possibility of placebo. She replies: 'Fine, whatever, just give me the paperwork.' Her baseline PHQ-9 is 21, she reports passive suicidal ideation without plan or intent (a protocol exclusion is active intent, which she does not meet), and she has a strong therapeutic relationship with the referring psychiatrist, who is also a sub-investigator on the trial. The coordinator feels pressure because enrollment is behind target with three slots to fill this month.
1. Evaluate whether this participant can provide valid informed consent at this moment, and identify the specific pressures on voluntariness and comprehension.
Read the worked answer
The consent as described is not validly obtained, for two independent reasons.
Comprehension: She has stated a factually incorrect belief ('guaranteed the real drug') that directly contradicts a core element of the study. Her subsequent 'fine, whatever' is acquiescence, not understanding. A participant who does not grasp that she may receive placebo has not consented to randomization - she has consented to something else. The investigator must correct the misconception and verify understanding before any signature counts.
Voluntariness: Two pressures interact. First, the referring psychiatrist is also a sub-investigator - a dual role in which the person she trusts for care is also the person who benefits from enrollment. Second, she is in an active depressive episode (PHQ-9 21) with passive suicidal ideation, a state that can affect decisional capacity and increase deference to authority.
Capacity: Passive ideation without plan or intent does not by itself disqualify her, and a depression diagnosis does not automatically mean incapacity. But decisional capacity should be assessed, not assumed - particularly where the participant is expressing a fixed false belief about the study.
Conclusion: Do not enroll on the current consent. Address the misconception, assess capacity, separate the treating and research roles, and re-consent only if she genuinely understands that she may receive placebo.
2. The coordinator notes that enrollment is behind target. How should that fact influence the decision, and what would you document?
Read the worked answer
It must not influence the decision at all - and the fact that it is being raised is itself a warning sign. Enrollment pressure is a recognized driver of consent shortcuts and eligibility over-interpretation. The correct framing: recruitment targets are a site-management problem, not a reason to lower the consent bar. A participant enrolled without valid consent is worse than an empty slot - it is a protocol deviation, a potential unanticipated problem, and a harm to the participant.
What to document:
- The participant's stated expectation ('guaranteed the real drug') and the investigator's correction of it - verbatim where possible.
- That understanding was re-checked and how (teach-back, specific questions about placebo).
- The capacity assessment and its basis.
- The discussion about the dual role of the referring psychiatrist and any steps taken (e.g., a different clinician obtaining consent, explicit assurance that declining will not affect her care).
- The outcome: enrolled, deferred, or not enrolled - and why.
If she cannot be re-consented with genuine understanding, the honest documentation is 'not enrolled due to inability to demonstrate understanding of randomization.' That is a defensible record; a signed form obtained under pressure is not.
3. Describe how you would restructure the consent conversation to address the dual-role and therapeutic-misconception issues.
Read the worked answer
Restructure rather than repeat:
- Separate the roles explicitly. Have someone other than her treating psychiatrist conduct or co-conduct the consent, and state plainly: 'Dr. X is involved in running this study. I am not part of your clinical care. Your decision here will not change the care you receive from Dr. X.'
- Surface and correct the misconception directly. Ask: 'What do you think your chances are of getting the active drug?' A participant who says '100%' has told you the consent failed. Then explain randomization concretely (e.g., 'like a coin flip; you have about a 50% chance of placebo') and re-ask.
- Use teach-back, not yes/no. Ask her to explain in her own words what placebo means, what she can do if she worsens, and that she can withdraw.
- Address the desperation behind the 'whatever.' Two years of failed treatments creates strong motivation to enroll - which is exactly when voluntariness and understanding need the most protection, not the least.
- Revisit capacity and safety given active symptoms; involve the clinical team per protocol.
- Only then offer the form, and document the entire process.